Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)

Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib (“the study drug”) to give to patients in combination with a routine chemotherapy drug called ifosfamide. 

Eligibility and criteria
IRB Number:
22-019876
Eligible age range:
5 years - 40 years
Clinical trial phase:
Phase I
Official title:
A phase I trial of Cabozantinib (XL184) in combination with high-dose Ifosfamide in adults and children with relapsed/refractory Ewing sarcoma and osteosarcoma (CaIRS trial)

What to expect
As a participant in the research, you will:
  • Take cabozantinib (the study drug) by mouth once a day, in combination with routine chemotherapy drug ifosfamide given intravenously on days 1-5 of each cycle
  • Complete frequent clinic visits at CHOP Philadelphia campus 
  • Have frequent blood tests
  • Have EKGs and echocardiograms for clinical care purposes
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
  • Have research genetic tests (if not previously done clinically)
  • Submit leftover tissue samples to the study repository
  • Have fresh tissue samples collected (if you have a routine biopsy)

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.